In a report published Wednesday, UBS Securities analyst Steven Valiquette downgraded the rating on Patterson Companies PDCO from Buy to Neutral, but reiterated the $46.00 price target.
In the report, UBS Securities noted, “Based on strong U.S. trends from dental/vet peers, and a much easier dental equip comp, we are comfortable with our $0.49 EPS view vs. Street's $0.48 for PDCO's F2Q14 results to be reported Thurs a.m. (11/21). However, the dental equip comps get much tougher in the back half of FY14, and with pressure on the P&L related to voluntary I/T investments this year, it seems the run-up in the stock (up 26% YTD) has now priced in most of the good news related to U.S. dental trends. With stock now at P/E of 18x on CY14E, and 10x EBITDA, we downgrade to Neutral.”
Patterson Companies closed on Tuesday at $42.88.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in